By Colin Kellaher
Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD.
In a filing with the Australian Securities Exchange Monday, Opthea requested the trading halt pending an announcement related to top-line results of a Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision.
The ASX said the halt will remain in place until the start of trading Wednesday unless Opthea issues an announcement sooner.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 11:26 ET (15:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。